Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Pipeline Review, H1 2018
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Pipeline Review, H1 2018
SUMMARY
According to the recently published report 'Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Pipeline Review, H1 2018'; Protein Phosphatase 2A (PP2A or EC 3.1.3.16) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes.
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Protein Phosphatase 2A (PP2A) is an enzyme encoded by the PPP2CA gene. PP2A plays important roles in regulation of cell cycle, signal transduction, cell differentiation, and transformation. Its activity is related to several diseases, including neurodegenerative diseases and cancer.
The report 'Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Pipeline Review, H1 2018' outlays comprehensive information on the Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 1 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Cardiovascular, Gastrointestinal, Ophthalmology and Respiratory which include indications Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Lung Cancer, Ovarian Cancer, Allergic Conjunctivitis, Alzheimer's Disease, Asthma, Brain Ischemia, Breast Cancer, Breast Tumor, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Chronic Obstructive Pulmonary Disease (COPD), Colon Cancer, Crohn's Disease (Regional Enteritis), Depression, Idiopathic Pulmonary Fibrosis, Melanoma, Myelodysplastic Syndrome, Myocardial Ischemia, Neuroblastoma, Pancreatic Cancer, Pheochromocytoma, Renal Cell Carcinoma, Sarcomas, Septic Shock, Solid Tumor, Ulcerative Colitis, Uveal Melanoma and Uveitis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Pipeline Review, H1 2018'; Protein Phosphatase 2A (PP2A or EC 3.1.3.16) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes.
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Protein Phosphatase 2A (PP2A) is an enzyme encoded by the PPP2CA gene. PP2A plays important roles in regulation of cell cycle, signal transduction, cell differentiation, and transformation. Its activity is related to several diseases, including neurodegenerative diseases and cancer.
The report 'Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Pipeline Review, H1 2018' outlays comprehensive information on the Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 1 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Cardiovascular, Gastrointestinal, Ophthalmology and Respiratory which include indications Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Lung Cancer, Ovarian Cancer, Allergic Conjunctivitis, Alzheimer's Disease, Asthma, Brain Ischemia, Breast Cancer, Breast Tumor, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Chronic Obstructive Pulmonary Disease (COPD), Colon Cancer, Crohn's Disease (Regional Enteritis), Depression, Idiopathic Pulmonary Fibrosis, Melanoma, Myelodysplastic Syndrome, Myocardial Ischemia, Neuroblastoma, Pancreatic Cancer, Pheochromocytoma, Renal Cell Carcinoma, Sarcomas, Septic Shock, Solid Tumor, Ulcerative Colitis, Uveal Melanoma and Uveitis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Protein Phosphatase 2A (PP2A or EC 3.1.3.16)
- The report reviews Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics and enlists all their major and minor projects
- The report assesses Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Protein Phosphatase 2A (PP2A or EC 3.1.3.16)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Protein Phosphatase 2A (PP2A or EC 3.1.3.16) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Overview
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Companies Involved in Therapeutics Development
Ampio Pharmaceuticals Inc
Lixte Biotechnology Holdings Inc
PEP-Therapy SAS
Re-Pharm Ltd
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Drug Profiles
LB-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NCE-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PEP-010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RP-0217 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate PP2A for Lung Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit PPP2R2A for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TD-X - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VEL-015 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Dormant Products
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Product Development Milestones
Featured News & Press Releases
Feb 09, 2018: LB-100, Lixte Biotechnology’s Protein Phosphatase 2A Inhibitor, Sensitizes BCR-ABL Leukemia Stem Cells to Targeted Therapy with Tyrosine Kinase Inhibitors
Jun 13, 2017: Re-Pharm and Cresset Discovery Services to attend BIO International for partnering
Apr 17, 2017: Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, LB-100, Reported to be a Potentiator of Immunotherapy in an Animal Model
Mar 09, 2017: Late-Breaking Abstract on LB-100, Lixte Biotechnology’s Protein Phosphatase 2A Inhibitor, in Combination with a PD-1 Inhibitor in an Animal Model to be Presented at the AACR Annual Meeting
Jan 04, 2017: First-In-Human Assessment of LB-100, Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, Published in Clinical Cancer Research
Nov 03, 2016: Re-Pharm to present at IDDST, Nanjing, China and available for one-to-one meetings
Mar 24, 2016: Re-Pharm compound with steroid-sparing properties granted second patent for ophthalmic indications
Feb 03, 2016: Lixte Biotechnology Holdings Lead Compound LB-100 Reported to Rapidly Improve Symptoms in a Rodent Model of Depression
Nov 24, 2015: Re-Pharm awarded patent for repurposed compound for treatment of inflammatory disorders
Nov 06, 2015: Lixte Biotechnology Holdings Announces That Its Novel Protein Phosphatase 2A Inhibitor Is Associated With Stabilization of Several Types Of Cancer Without Dose-Limiting Toxicity
Sep 17, 2015: Lixte Biotechnology Holdings Engages BioPharmaWorks to Enhance Development of Its Pipeline of Novel Compounds
Feb 25, 2015: Lixte Biotechnology's Lead Compound Reported To Be Active Against Hematologic Cancers In Pre-Clinical Studies
Feb 10, 2015: Re-Pharm identifies novel anti-inflammatory activity for existing compound
Jan 23, 2015: Lixte Biotechnology Holdings Announces Expansion of Clinical Sites for Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100
Nov 06, 2014: Lixte's LB-100 Selected as One of Informa and Kantar Health's 2014 Top 10 Most Interesting Oncology Projects to Watch
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Overview
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Companies Involved in Therapeutics Development
Ampio Pharmaceuticals Inc
Lixte Biotechnology Holdings Inc
PEP-Therapy SAS
Re-Pharm Ltd
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Drug Profiles
LB-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NCE-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PEP-010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RP-0217 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate PP2A for Lung Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit PPP2R2A for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TD-X - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VEL-015 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Dormant Products
Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Product Development Milestones
Featured News & Press Releases
Feb 09, 2018: LB-100, Lixte Biotechnology’s Protein Phosphatase 2A Inhibitor, Sensitizes BCR-ABL Leukemia Stem Cells to Targeted Therapy with Tyrosine Kinase Inhibitors
Jun 13, 2017: Re-Pharm and Cresset Discovery Services to attend BIO International for partnering
Apr 17, 2017: Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, LB-100, Reported to be a Potentiator of Immunotherapy in an Animal Model
Mar 09, 2017: Late-Breaking Abstract on LB-100, Lixte Biotechnology’s Protein Phosphatase 2A Inhibitor, in Combination with a PD-1 Inhibitor in an Animal Model to be Presented at the AACR Annual Meeting
Jan 04, 2017: First-In-Human Assessment of LB-100, Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, Published in Clinical Cancer Research
Nov 03, 2016: Re-Pharm to present at IDDST, Nanjing, China and available for one-to-one meetings
Mar 24, 2016: Re-Pharm compound with steroid-sparing properties granted second patent for ophthalmic indications
Feb 03, 2016: Lixte Biotechnology Holdings Lead Compound LB-100 Reported to Rapidly Improve Symptoms in a Rodent Model of Depression
Nov 24, 2015: Re-Pharm awarded patent for repurposed compound for treatment of inflammatory disorders
Nov 06, 2015: Lixte Biotechnology Holdings Announces That Its Novel Protein Phosphatase 2A Inhibitor Is Associated With Stabilization of Several Types Of Cancer Without Dose-Limiting Toxicity
Sep 17, 2015: Lixte Biotechnology Holdings Engages BioPharmaWorks to Enhance Development of Its Pipeline of Novel Compounds
Feb 25, 2015: Lixte Biotechnology's Lead Compound Reported To Be Active Against Hematologic Cancers In Pre-Clinical Studies
Feb 10, 2015: Re-Pharm identifies novel anti-inflammatory activity for existing compound
Jan 23, 2015: Lixte Biotechnology Holdings Announces Expansion of Clinical Sites for Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100
Nov 06, 2014: Lixte's LB-100 Selected as One of Informa and Kantar Health's 2014 Top 10 Most Interesting Oncology Projects to Watch
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.1), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Ampio Pharmaceuticals Inc, H1 2018
Pipeline by Lixte Biotechnology Holdings Inc, H1 2018
Pipeline by PEP-Therapy SAS, H1 2018
Pipeline by Re-Pharm Ltd, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products under Development by Indications, H1 2018 (Contd.1), H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Ampio Pharmaceuticals Inc, H1 2018
Pipeline by Lixte Biotechnology Holdings Inc, H1 2018
Pipeline by PEP-Therapy SAS, H1 2018
Pipeline by Re-Pharm Ltd, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
Ampio Pharmaceuticals Inc
Lixte Biotechnology Holdings Inc
PEP-Therapy SAS
Re-Pharm Ltd
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
Ampio Pharmaceuticals Inc
Lixte Biotechnology Holdings Inc
PEP-Therapy SAS
Re-Pharm Ltd
